PACS Group Q2 Revenue Reaches $1.43B, Net Income Climbs 50%, Yet Material Weaknesses and Federal Probes Persist
PACS has more than doubled off its 52-week low of $7.5.
Summary
PACS Group reported Q2 2026 revenue of $1.43 billion (+9.1% YoY) and net income of $76.3 million (+49.8%), but disclosed unremediated material weaknesses, ongoing DOJ/SEC investigations, and a new CEO 10b5-1 plan for up to 2 million shares.
Key Events · Earnings and Guidance · PACS
-
Q2 Revenue and Earnings Surge
Revenue reached $1.43 billion, up 9.1% year-over-year, while net income attributable to PACS Group jumped 49.8% to $76.4 million. Adjusted EBITDA rose to $166.8 million.
-
Material Weaknesses Unremediated
Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to previously identified material weaknesses in internal control over financial reporting. Remediation efforts are ongoing but not yet complete.
-
Multiple Federal Investigations Ongoing
The company remains subject to several DOJ civil investigative demands and an SEC investigation into accounting, financial reporting, and internal controls. No loss can be estimated at this time.
-
CEO Adopts 10b5-1 Trading Plan
On May 18, 2026, CEO Jason Murray adopted a Rule 10b5-1 plan to sell up to 2,000,000 shares through May 15, 2027, adding to a pattern of significant insider selling over the past 90 days.
Analysis · PACS · Industrial Applications And Services
A strong quarter saw revenue rise 9.1% and net income surge nearly 50%, but the 10-Q makes clear that material weaknesses in internal controls remain unremediated and multiple federal investigations are ongoing. Adding to the overhang, CEO Jason Murray adopted a 10b5-1 plan to sell up to 2 million shares, extending a pattern of insider selling. While operational momentum is evident, the unresolved governance and legal risks could materially affect the investment thesis.
At the time of this filing, PACS was trading at $44.62 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $7.50 to $48.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.